Active Mental Health Psychology & Behaviour

Supporting people with psychosis: a real world deployment of CareLoop in the US.

Funder Wellcome Charity-funded
Associated organisations Atrius Health · CareLoop Health LTD · Reliant Medical Group Europe PMC affiliations are not treated as award recipients or mapped locations.
Funding £187K
Period Oct 2025 — Oct 2026

In plain English

AI plain-English summary

A digital platform called CareLoop, already used in the UK to support people with psychosis, is being deployed in the US for the first time to test whether it works outside the British healthcare system. CareLoop is a Class I medical device that helps people with severe mental illness manage their condition, and it carries a NICE recommendation in the UK. But the US has a different healthcare landscape—different regulations, different patient populations, and different infrastructure. Without real-world data from a US setting, it is unclear whether the platform will be adopted, accepted, or effective there. This project will collect that data, working directly with service users and clinicians to identify practical barriers—such as cost, internet access, or cultural attitudes—and figure out how to overcome them. If successful, the findings will guide iterative improvements to CareLoop and shape its commercial rollout in the US and eventually in low- and middle-income countries, where affordability and infrastructure constraints pose additional challenges. The project is not fundamental science; it is an implementation study designed to solve a concrete, practical problem: getting a proven digital tool to work in a new context.

View original technical description
This project proposes a real world evaluation of the CareLoop platform in a mental healthcare setting in the US. The CareLoop product has been developed in the UK to support people with severe mental illness. It has an expansive evidence base and has been extensively tested through a series of clinical trials. The CareLoop product is now NICE-recommended through the Early Value Assessment process in the UK and is registered as a Class I medical device with the UK Medicines and Health Regulatory Authority. However, it has never before been used in the US.This real world project will collect data on clinical outcomes, user acceptability, and implementation. We will work closely with service users and healthcare professionals to identify and overcome the practical barriers and enablers to adoption. The data we collect will inform iterative improvements to the CareLoop product and implementation model. Crucially, the project will support the development of the CareLoop commercialization strategy, bringing critical insights to the CareLoop approach to the U.S. and global markets. The project will also inform the CareLoop strategy to low and middle income countries (LMICs) where affordability, infrastructure limitations, culturally sensitive technical adaptations and health system constraints are key.

View the original record at the funder ↗

Researchers

Mara Eyllon (EPMC Awardee)Pauline Whelan (EPMC Awardee)Simona Sava (EPMC Awardee)Zoe Blake (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Personalised monitoring and enhanced self-management in mental health (CareLoop)
Industrial Research to generate evidence for submission to NICE using a novel, real-world trial design for a technology-enabled, blended service for Cardiac Rehabilitation.
CARE-PAC: The Care and Support System for Patients and Carers receiving palliative and end-of life-care
Designed for Independence – a new model of (self)-care in medicines management among older people
Prototype building, testing and Beta product development for a new digital therapeutic to support adolescents with low mood / depression

Original classification

Discretionary Award

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.